Video

Dr. Slovin shares her experience with CAR T-cell therapy in prostate cancer

Author(s):

Urology Times staff
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Susan F. Slovin, MD, PhD, medical oncologist, associate vice chair, Academic Affairs, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses her experience with CAR T-cell therapy as an emerging treatment for patients with prostate cancer.

      Related Videos
      Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
      Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
      Rebecca A. Campbell, MD, answers a question during a Zoom video interview
      Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
      1 expert in this video
      Comparing Trials Studying Treatment Intensification In mHSPC
      An Overview of the ARANOTE Trial
      An Overview of the ARANOTE Trial
      Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
      Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
      Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
      Stephen J. Freedland, MD, on the benefits of mCRPC treatments translating to the real world
      Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
      Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
      Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
      Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
      Study data point to gender disparities in oncology research citations
      Study data point to gender disparities in oncology research citations
      Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
      Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
      Related Content
      Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
      May 15th 2025

      Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

      Tracey L. Krupski, MD Jeunice Owens-Walton, MD
      "The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC
      May 6th 2025

      Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

      Hannah Clarke
      Initial study results may be available as soon as the first half of 2026.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
      Published: April 29th 2025 | Updated: April 29th 2025

      Ultra-low PSA responses are more prevalent with darolutamide plus ADT

      Benjamin P. Saylor
      The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
      ARANOTE substudy highlights benefits of darolutamide in Black men
      April 28th 2025

      ARANOTE substudy highlights benefits of darolutamide in Black men

      Benjamin P. Saylor
      The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.
      © 2025 MJH Life Sciences

      All rights reserved.